Changes in serological biomarkers of liver function and connective tissue turnover in chronic hepatitis B during lamivudine therapy

Biomarkers

Volumn 10, Issue 6, 2005, Pages 475-484

  Maxwell, Paul R ^a   Flisiak, R ^b  

^a STOBHILL HOSPITAL   (United Kingdom)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Chronic hepatitis; Fibrosis; Lamivudine; Receiver operating characteristic (ROC) analysis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CARBOXY TERMINAL TELOPEPTIDE; COLLAGEN TYPE 4; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; BIOLOGICAL MARKER; PROCOLLAGEN; PROCOLLAGEN TYPE 1 AMINOPROPEPTIDE; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONNECTIVE TISSUE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; LIVER FIBROSIS; LIVER FUNCTION TEST; MALE; PROTEIN BLOOD LEVEL; ROC CURVE; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; AMINO TERMINAL SEQUENCE; BLOOD SAMPLING; DIAGNOSTIC ACCURACY; DRUG DOSE REGIMEN; HEPATITIS B VIRUS; LIVER TOXICITY; NONHUMAN; PATIENT MONITORING; RECEIVER OPERATING CHARACTERISTIC; SEROLOGY; TISSUE METABOLISM;

ADULT; AREA UNDER CURVE; BIOLOGICAL MARKERS; CONNECTIVE TISSUE; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; ROC CURVE;

HEPATITIS B VIRUS;

EID: 30844466188     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500500353760     Document Type: Article

References (26)

1. Beasley, RP and Hwang, LY and Lin, CC and Chien, CS. (1981) Hepatocellular carcinoma and hepatitis B virus: A prospective study of 22707 men in Taiwan Lancet, ii, pp. 112-133.
2. Elomaa, I and Virkkunen, P and Risteli, L and Risteli, J. (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type 1 collagen (ICTP) is a useful prognostic indicator in multiple myeloma British Journal of Cancer, 66, pp. 337-341.
3. Flisiak, R and Maxwell, P and Prokopowicz, D and Timms, PM and Panasuik, A. (2002) Plasma tissue inhibitor of metalloproteinase-1 and transforming growth factor β1 - possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis Hepato-Gastroenterology, 49, pp. 1369-1372.
4. Hu, KQ. (2005) A practical approach to chronic hepatitis B International Journal of Medical Science, 2, pp. 17-23.
5. Lai, CL and Chien, RN and Leung, NW and Chang, TT and Guan, R and Tai, DI. (1998) A one-year trial of lamivudine for chronic hepatitis B New England Journal of Medicine, 339, pp. 61-68.
6. Liaw, YF. (2002) Management of patients with chronic hepatitis B Journal of Gastro-Hepatology, 17, pp. 406-408.
7. Liaw, YF and Tai, DI and Chu, CM and Chen, TJ. (1988) The development of cirrhosis in patients with chronic type B hepatitis: A prospective study Hepatology, 8, pp. 493-496.
8. Lin, DY and Chu, CM and Sheen, IS and Liaw, YF. (1995) Serum carboxyterminal propeptide of type 1 procollagen to amino terminal propeptide of type 111 procollagen ratio is a better indicator than each single propeptide and 7S domain type IV collagen for progressive fibrogenesis in chronic viral liver diseases Digestive Disease Science, 40, pp. 21-27.
9. Malaguarnera, M and Restuccia, S and Ferlito, L and Mazzoleni, G and Giugno, I and Pistone, G. (2001) Antiviral drugs in chronic hepatitis B: review and meta-analysis International Journal of Clinical Pharmacology and Therapeutics, 39, pp. 4-11.
10. McMahon, BJ and Alward, WLM and Hall, DB. (1985) Acute hepatitis B infection: Relation of age to the clinical expression of the disease and subsequent development of carrier-state Journal of Infectious Diseases, 151, pp. 599-603.
11. Melkko, J and Neimi, S and Ristelli, L. (1990) Radioimmunoassay of carboxy-terminal propeptide of type 1 procollagen (PICP) Clinical Chemistry, 36, pp. 1328-1332.
12. Nelson, DR and Lim, HL and Oliver, D and Qian, KP and Lau, JYN. (1995) Alpha glutathione-S-transferase as a marker of hepatocellular damage in chronic hepatitis C American Journal of Clinical Pathology 104, pp. 193-198
13. Perrillo, RP and Lai, CL and Liaw, YF and Dienstag, JL and Schiff, ER and Schalm, SW and Heathcote, EJ and Brown, NA and Atkins, M and Woessner, M and Gardner, SD. (2002) Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B Hepatology, 36, pp. 186-191.
14. Regev, A and Schiff, ER. (2001) Drug therapy for hepatitis B Advances in Internal Medicine, 46, pp. 107-135.
15. Ristelli, J and Niemi, S and Trivedi, P. (1990) Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type 111 procollagen (P3NP) Clinical Chemistry, 36, pp. 421-426.
16. Scheuer, PJ. (1991) Classification of chronic viral hepatitis: A need for reassessment Journal of Hepatology, 13, pp. 372-374.
17. Schuppan, D and Besser, M and Schwarting, R. (1986) Radioimmunoassay for the carboxy-terminal cross-linking domain of type 1V (basement membrane) procollagen in body fluids Journal of Clinical Investigation, 78, pp. 241-248.
18. Shindo, M and Hamada, K and Nishioji, K and Muramatsu, A and Oda, Y and Okuno, T. (2004) The predictive value of liver fibrosis in determining the effectiveness of interferon and lamivudine therapies for chronic hepatitis B Journal of Gastroenterology, 39, pp. 260-267.
19. Suzuki, Y and Kumada, H and Chayama, K and Arase, Y and Saitoh, S. (1999) Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection Journal of Hepatology, 30, pp. 743-748.
20. Tassopoulos, NC and Volpes, R and Pastore, G and Heathcote, J and Buti, M and Goldin, RD. (1999) Efficacy of lamivudine in patients with hepatitis B antigen negative hepatitis B virus DNA positive (precore mutant) chronic hepatitis B Hepatology, 29, pp. 889-896.
21. Tsutsumi, M and Takase, S and Urashima, S and Ueshima, Y and Kawahara, H and Takada, A. (1996) Serum markers for hepatic fibrosis in alcoholic liver disease: Which is the best marker, type III procollagen, type IV collagen, laminin, tissue inhibitor of metalloproteinase or prolyl hydroxylase? Alcoholism Clinical and Experimental Research, 20, pp. 1512 - 1517.
22. Tsutsumi, M and Urashima, S and Matsuda, Y and Takase, S and Takada, A. (1993) Changes in type IV collagen content in livers of patients with alcoholic liver disease Hepatology, 17, pp. 820 - 827.
23. Ueno, T and Inuzuka, S and Torimura, T and Oohira, H and Ko, H and Obata, K and Sata, M and Yashida, H and Tanikawa, K. (1992) Significance of serum type IV collagen levels in various liver diseases Scandinavian Journal of Gastroenterology, 27, pp. 513 - 520.
24. Yabu, K and Kiyosawa, K and Mori, H and Matsumoto, A and Yoshizawa, K and Tanaka, E and Furuta, S. (1994) Serum collagen IV for the assessment of fibrosis and resistance to interferon therapy in chronic hepatitis C Scandinavian Journal of Gastroenterology, 29, pp. 474-479.
25. Zachariae, H and Heickendorff, L and Sogaard, H. (2001) The value of amino-terminal propeptide of type 111 procollagen in routine screening for methotrexate induced liver fibrosis: A 10 year follow-up British Journal of Dermatology, 143, pp. 100-103.
26. Zoulim, F. (2002) A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection Drug Safety, 25, pp. 497-510.